SCHEMBL4849751

SCHEMBL4849751

COC(=O)c1cc2c(cc1OC)Nc1cc(Cl)ccc1C(=O)N2

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 15/20 0.62
ROCK2 O75116 1/20 0.51
CSF1R P07333 1/20 0.51
KDR P35968 1/20 0.51
FLT3 P36888 1/20 0.51
GSK3A P49840 1/20 0.51
GSK3B P49841 1/20 0.51
CDK5 Q00535 1/20 0.51
ROCK1 Q13464 1/20 0.51
SLK Q9H2G2 1/20 0.51
IRAK4 Q9NWZ3 1/20 0.51
TUBB4A P04350 1/20 0.47
TUBB P07437 1/20 0.47
TUBA3C P0DPH7 1/20 0.47
TUBA1B P68363 1/20 0.47
TUBA4A P68366 1/20 0.47
TUBB4B P68371 1/20 0.47
TUBB3 Q13509 1/20 0.47
TUBB2A Q13885 1/20 0.47
TUBB8 Q3ZCM7 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4856796 0.82 CHEK1 (0.60) CHEK1ROCK2KDRFLT3GSK3A
SCHEMBL4858837 0.82 CHEK1 (0.60) CHEK1ROCK2KDRFLT3GSK3A
SCHEMBL4855349 0.81 CHEK1 (0.46) CHEK1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL4855475 0.81 TUBB4A (0.52) CHEK1KDRGSK3BTUBB4ATUBB
SCHEMBL4854936 0.81 TUBB4A (0.52) CHEK1KDRGSK3BTUBB4ATUBB
SCHEMBL4847952 0.80 CHEK1 (0.55) CHEK1ROCK2CSF1RKDRFLT3
SCHEMBL4849130 0.80 CHEK1 (0.55) CHEK1ROCK2CSF1RKDRFLT3
SCHEMBL4855598 0.79 CHEK1 (0.65) CHEK1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL4865764 0.79 CHEK1 (0.62) CHEK1KDRTUBB4ATUBBTUBA3C
SCHEMBL4849525 0.79 CHEK1 (0.48) CHEK1KDRTUBB4ATUBBTUBA3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1606268-B1 5,10-DIHYDRO-11H-DIBENZO[B,E][1,4]DIAZEPIN-11-ONE AS KINASE INHIBITORS ABBVIE INC (US) 2015-05-20 EP disclosed
US-7456169-B2 Heterocyclic kinase inhibitors ABBOTT LABORATORIES INC. (US) 2008-11-25 US disclosed
US-20070254867-A1 Heterocyclic Kinase Inhibitors ABBVIE INC. 2007-11-01 US disclosed
US-20040254159-A1 Heterocyclic kinase inhibitors ABBOTT LABORATORIES 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254159-A1 Heterocyclic kinase inhibitors MAP3K20, MAP3K19, MAP3K1 CHEK1 46/4885ROCK2 486/4885CSF1R 2559/4885
US-20070254867-A1 Heterocyclic Kinase Inhibitors MAP3K20, MAP3K19, MAP4K2 CHEK1 38/4885ROCK2 483/4885CSF1R 3275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.